|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
INDINAVIR MAY INCREASE PLASMA CONCENTRATION OF THE DRUG
|
INDINAVIR MAY INCREASE PLASMA CONCENTRATION OF THE DRUG
|
KETAMINE EFFECT IS PROLONGED WITH SUBSEQUENT DELAY IN RECOVERY DUE TO CONCOMITANT USE
|
CIMETIDINE INCREASES ITS PLASMA CONCENTRATION AND HENCE BIOAVAILABILITY
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
CLOBAZAM CONCURRENT ADMINISTRATION WITH THE DRUG LEADS TO REDUCED CLEARANCE OF CLOBAZAM, HENCE THE DOSE SHOULD BE REDUCED TO ONE THIRD
|
OPIOD ANALGESICS IN HIGH DOSE MAY RESULT IN DROP IN HEART RATE AND CARDIAC OUTPUT
|
OPIATES DELAY ABSORPTION DUE TO SLOW GASTRIC EMPTYING
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
DEXTROPROPOXYPHENE MAY REDUCE ITS METABOLISM LEADING TO ITS INCREASED SERUM LEVELS AND TOXICITY
|
DEXTROPROPOXYPHENE MAY REDUCE ITS METABOLISM LEADING TO ITS INCREASED SERUM LEVELS AND TOXICITY
|
DEXTROPROPOXYPHENE MAY REDUCE ITS METABOLISM LEADING TO ITS INCREASED SERUM LEVELS AND TOXICITY
|
DEXTROPROPOXYPHENE MAY REDUCE ITS METABOLISM LEADING TO ITS INCREASED SERUM LEVELS AND TOXICITY
|
DEXTROPROPOXYPHENE MAY REDUCE ITS METABOLISM LEADING TO ITS INCREASED SERUM LEVELS AND TOXICITY
|
DEXTROPROPOXYPHENE MAY REDUCE ITS METABOLISM LEADING TO ITS INCREASED SERUM LEVELS AND TOXICITY
|
DEXTROPROPOXYPHENE MAY REDUCE ITS METABOLISM LEADING TO ITS INCREASED SERUM LEVELS AND TOXICITY
|
DEXTROPROPOXYPHENE MAY REDUCE ITS METABOLISM LEADING TO ITS INCREASED SERUM LEVELS AND TOXICITY
|
DEXTROPROPOXYPHENE MAY REDUCE ITS METABOLISM LEADING TO ITS INCREASED SERUM LEVELS AND TOXICITY
|
DEXTROPROPOXYPHENE MAY REDUCE ITS METABOLISM LEADING TO ITS INCREASED SERUM LEVELS AND TOXICITY
|
DEXTROPROPOXYPHENE MAY REDUCE ITS METABOLISM LEADING TO ITS INCREASED SERUM LEVELS AND TOXICITY
|
DEXTROPROPOXYPHENE MAY REDUCE ITS METABOLISM LEADING TO ITS INCREASED SERUM LEVELS AND TOXICITY
|
DEXTROPROPOXYPHENE MAY REDUCE ITS METABOLISM LEADING TO ITS INCREASED SERUM LEVELS AND TOXICITY
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
METOCLOPRAMIDE EFFECTS ON G.I. MOTILITY ARE ANTAGONISED BY THE DRUG
|
PANTAZOCINE MAY CAUSE INCREASED RISK OF RESPIRATORY DEPRESSION & HYPOTENSION
|
RITONAVIR INCREASES PLASMA CONCENTRATION OF THE DRUG & SO INCREASED CHANCES OF SIDE EFFECTS
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF POSTOPERATIVE RESPIRATORY DEPRESSION OR ENHANCE IT
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
RIFAMPICIN MAY ACCELERATES METABOLISM OF THE DRUG & MAY CAUSE DECREASED PLASMA CONCENTRATION
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|